Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $10.00 at Barclays

Karyopharm Therapeutics (NASDAQ:KPTI) had its target price boosted by Barclays from $5.00 to $10.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research firms also recently weighed in on KPTI. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright lifted their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $45.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $4.92 on Tuesday. The company has a market capitalization of $42.16 million, a P/E ratio of -4.82 and a beta of 0.33. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $17.85. The stock has a 50 day moving average price of $5.50 and a 200-day moving average price of $8.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, May 12th. The company reported ($2.77) EPS for the quarter, beating analysts’ consensus estimates of ($4.21) by $1.44. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $35.12 million. As a group, equities analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of KPTI. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $27,000. Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $32,000. Two Sigma Advisers LP boosted its position in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $85,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).